Research Library
In-depth research, organized by category.
Published literature relevant to each category of compound in the Nordvik catalog. This is a starting point for your own review, not a substitute for it — read the primary sources before drawing conclusions, and note that literature discussing a compound’s studied mechanisms is not an endorsement of any use outside a research setting.
Growth Hormone Secretagogues
Covers CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, and HGH Frag 176-191 — compounds studied for their interaction with the ghrelin receptor or growth-hormone-releasing hormone (GHRH) pathway.
Chanoine JP, Wong AC, Barrios V. “Ghrelin and the growth hormone secretagogue receptor in growth and development.”
International Journal of Obesity, 2009.
PMID 19363508Müller TD, et al. “Ghrelin.”
Molecular Metabolism, 2015.
PMID 26042199Dominikowski A, et al. “The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.”
Frontiers in Endocrinology, 2026.
PMID 42395176
Tissue Repair Peptides
Covers BPC-157, TB-500, and GHK-Cu, along with blend formulations combining them — compounds studied in preclinical models of soft-tissue healing, angiogenesis, and collagen remodeling.
Gwyer D, Wragg NM, Wilson SL. “Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.”
Cell and Tissue Research, 2019.
PMID 30915550Seiwerth S, et al. “Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.”
Frontiers in Pharmacology, 2021.
PMID 34267654Rahman OF, et al. “Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.”
JAAOS Global Research & Reviews, 2026.
PMID 41490200
GLP-1 and Metabolic Peptides
Covers Semaglutide, Tirzepatide, Retatrutide, and AOD9604 — incretin-pathway compounds studied in metabolic and glycemic-control research. Semaglutide and tirzepatide have FDA-approved pharmaceutical counterparts for human therapeutic use; the material we supply is a separate research-grade compound, not the approved product.
Liu QK. “Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.”
Frontiers in Endocrinology, 2024.
PMID 39114288Moiz A, et al. “Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation.”
The American Journal of Medicine, 2025.
PMID 39892489Nauck MA, D’Alessio DA. “Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction.”
Cardiovascular Diabetology, 2022.
PMID 36050763
Neuropeptide and Cognitive Research
Covers Semax, Selank, and DSIP — heptapeptides and neuropeptides originating largely from Russian neuropharmacology research, studied for anxiolytic, nootropic, and sleep-regulatory activity in animal models.
Liapina LA, et al. “Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application.”
Izvestiia Akademii Nauk. Seriia Biologicheskaia, 2006.
PMID 16634437Ashmarin IP, et al. “Highly stable regulatory oligopeptides: experience and applications.”
Patologicheskaia Fiziologiia i Eksperimental’naia Terapiia, 2003.
PMID 14682258
Cellular and Longevity Research
Covers NAD+, Epithalon, and MOTS-c — compounds studied in relation to cellular energy metabolism, mitochondrial signaling, and aging biology. The citations below focus on NAD+ pathway biology broadly, which is directly relevant background for this category, rather than compound-specific trials for every peptide listed.
Covarrubias AJ, Perrone R, Grozio A, Verdin E. “NAD+ metabolism and its roles in cellular processes during ageing.”
Nature Reviews Molecular Cell Biology, 2021.
PMID 33353981Verdin E. “NAD+ in aging, metabolism, and neurodegeneration.”
Science, 2015.
PMID 26785480Chini CCS, et al. “NAD metabolism: Role in senescence regulation and aging.”
Aging Cell, 2024.
PMID 37424179
Melanocortin Receptor Research
Covers Melanotan-2 — studied for melanocortin receptor activity. Included below alongside the research literature is a documented adverse-event case report; we think it belongs here precisely because “Documented” and “Transparent” mean including findings that complicate a compound’s profile, not just the ones that support it.
Wessells H, et al. “Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.”
International Journal of Impotence Research, 2000.
PMID 11035391Peters B, et al. “Melanotan II: a possible cause of renal infarction: review of the literature and case report.”
CEN Case Reports, 2020.
PMID 31953620